Zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric cancer. Currently, zolbetuximab has not yet been launched in China. This article provides a detailed explanation of zolbetuximab, including its indications, dosage and administration, side effects, contraindications, and clinical efficacy.
Zolbetuximab: Indications, Dosage and Administration, and Precautions
(I) Indications
Zolbetuximab is indicated for the treatment of unresectable, advanced, and recurrent gastric cancer positive for Claudin 18.2 (CLDN18.2).
(II) Recommended Dosage
When used in combination with other antineoplastic therapeutic drugs, the recommended initial dose of zolbetuximab for adult patients is 800 mg/m². For the second and subsequent doses, the dosage can be reduced to 600 mg/m², and after an interval of 3 weeks, it can be further reduced to 400 mg/m². The drug is administered via intravenous infusion over a period of more than 2 hours, with an interval of every 2 weeks.
(III) Target Population
Adults. Pregnant women, lactating women, children, and elderly patients should use this drug under the guidance of a doctor.
(IV) Contraindications
Patients with a severe allergic history to the components of zolbetuximab are contraindicated from using this drug.
(V) Side Effects
Common side effects include allergic reactions, and severe nausea or vomiting.
Other adverse reactions include neutropenia, anemia, thrombocytopenia, leukopenia, decreased appetite, hypoalbuminemia, hypertension, abdominal pain, constipation, diarrhea, fatigue, asthenia, lassitude, fever, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), and weight loss. For more adverse reactions, please refer to the drug package insert.
(VI) Precautions
1. Precautions for Pharmaceutical Preparation
(1) Reconstitution
Zolbetuximab needs to be reconstituted with 5.0 mL of water for injection specified in the Japanese Pharmacopoeia, resulting in a drug concentration of 20 mg/mL after reconstitution. Aseptic conditions must be maintained during reconstitution: the water for injection should be slowly injected along the inner wall of the zolbetuximab vial. Shaking is not allowed; instead, the solution should be gently stirred until it is completely dissolved.
After reconstitution, the solution must be allowed to stand to let air bubbles in the vial disappear. Direct sunlight exposure should be avoided throughout the entire preparation process. The reconstituted solution should be a clear liquid ranging from colorless to slightly yellow.
(2) Dilution
Draw the required volume of the reconstituted solution from the vial and add it to an intravenous infusion bag containing normal saline, adjusting the diluted concentration to 2.0 mg/mL. Gently invert the infusion bag to mix the solution, avoiding foaming, and ensure no direct sunlight exposure throughout the process. Visually inspect the diluted solution for the presence of particles; if particles are found, the solution must not be used.
The diluted drug should be used promptly. Under room temperature, the diluted drug must be administered within 6 hours. If storage of the diluted drug is necessary, it should be stored at 2-8°C and used as soon as possible within 24 hours after dilution. Any unused residual solution should be discarded promptly. Do not use the same infusion line for concurrent administration with other drugs.
(VII) Drug Interactions
Not yet determined.
(VIII) Storage Conditions
Store at 2-8°C.
【Kind Reminder】: The package inserts of some products are updated frequently. Please refer to the actual product for the most accurate information.
